68Ga标记TATE类似物的比较评价:螯合剂对显像的影响
本研究比较了以NOTA和DOTA为双功能螯合剂制备的68Ga-NOTA-TATE与68Ga-DOTA-TATE的体外稳定性和体内显像特征。体外实验显示68Ga-NOTA-TATE稳定性更高、蛋白结合率更低;在AR42J荷瘤小鼠中两者肿瘤亲和力相当;健康志愿者显像示分布模式相似,但68Ga-NOTA-TATE在肝脏等多数器官的SUVmax较低。
要点
- 68Ga-NOTA-TATE在3小时孵育后的体外稳定性≥99%,高于68Ga-DOTA-TATE的≥95%。
- 68Ga-NOTA-TATE的血浆蛋白结合率为12.12%,低于68Ga-DOTA-TATE的30.6%。
- 健康志愿者显像中68Ga-NOTA-TATE在肝脏等多数器官的SUVmax较低,肝脏为4.2 vs 10.1。
核心结论
- 68Ga-NOTA-TATE与68Ga-DOTA-TATE在AR42J小鼠模型中显示相当的肿瘤摄取。
- 初步临床研究显示68Ga-NOTA-TATE可能降低肝脏等主要器官的本底摄取。
- 尽管受试者数量有限,仍需进一步研究68Ga-NOTA-TATE用于检测SSTR2阳性神经内分泌肿瘤。
研究设计与样本
- 研究比较了以NOTA和DOTA为双功能螯合剂制备的68Ga标记TATE类似物的药代动力学与显像特征。
- 体外实验评估放射化学纯度、体外稳定性和血浆蛋白结合率。
- 在AR42J荷瘤小鼠中进行体内药代动力学评价,并在健康志愿者中进行显像研究。
主要发现
- 68Ga-NOTA-TATE与68Ga-DOTA-TATE均获得高放射化学纯度。
- 68Ga-NOTA-TATE的体外稳定性(≥99%)高于68Ga-DOTA-TATE(≥95%)(3小时孵育后)。
- 68Ga-NOTA-TATE的水溶解度(分配系数-1.76±0.06 vs -2.72±0.16)和血浆蛋白结合率(12.12% vs 30.6%)均低于68Ga-DOTA-TATE。
- 在AR42J荷瘤小鼠中观察到药代动力学差异,但1小时内肿瘤亲和力相当。
- 健康志愿者显像显示两种显像剂分布模式相似,但各器官SUVmax不同;肾脏SUVmax几乎相同,68Ga-NOTA-TATE在肝脏等多数其他器官的SUVmax较低(肝脏4.2 vs 10.1)。
关键数值与推荐
- 68Ga-NOTA-TATE体外稳定性≥99%,68Ga-DOTA-TATE≥95%(3小时孵育后)。
- 68Ga-NOTA-TATE分配系数-1.76±0.06,68Ga-DOTA-TATE为-2.72±0.16。
- 68Ga-NOTA-TATE血浆蛋白结合率12.12%,68Ga-DOTA-TATE为30.6%。
- 健康志愿者肝脏SUVmax:68Ga-NOTA-TATE 4.2 vs 68Ga-DOTA-TATE 10.1。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出受试者数量有限。
- 原文结论提出需进一步研究68Ga-NOTA-TATE用于检测SSTR2阳性神经内分泌肿瘤。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: 68Ga-labelled peptides targeting somatostatin receptor 2 (SSTR2) have demonstrated encouraging results in managing patients with neuroendocrine tumours (NETs). In addition to metal chelation, bifunctional chelators have also been found to impact imaging outcomes due to their differences in stability, charge, hydrophilicity, etc. In the present work, a comparative pharmacokinetic evaluation and imaging characteristics were performed between 68Ga-labelled somatostatin analogues (TATE) using NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid) and DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) as bifunctional chelating agents (BFCAs). RESULTS: Both 68Ga-NOTA-TATE and 68Ga-DOTA-TATE were obtained with high radiochemical purity. 68Ga-NOTA-TATE demonstrated higher in vitro stability (≥ 99%) than 68Ga-DOTA-TATE (≥ 95%) after 3 h of incubation. The water solubilities (partition coefficients, - 1.76 ± 0.06 vs. - 2.72 ± 0.16) and plasma protein binding rates (12.12% vs. 30.6%) were lower for 68Ga-NOTA-TATE than for 68Ga-DOTA-TATE. Differential pharmacokinetics and comparable tumour affinities (within 1 h) were observed in AR42J tumour-bearing mice. Healthy volunteer imaging studies showed comparable distribution patterns of these two imaging agents. However, the maximum standardized uptake values (SUVmax) of the two tracers varied in each organ. The two PET agents demonstrated almost identical SUVmax values in the kidneys. 68Ga-NOTA-TATE did have a lower SUVmax in most other organs compared with 68Ga-DOTA-TATE, including the liver (4.2 vs. 10.1), potentially due to the lower protein binding rate. CONCLUSION: 68Ga-NOTA-TATE and 68Ga-DOTA-TATE demonstrated comparable tumour uptake in an AR42J mouse model. An initial clinical study revealed that 68Ga-NOTA-TATE may have reduced background uptake in the major organs such as the liver. Although the subject numbers were limited, further investigation of 68Ga-NOTA-TATE is warranted for detecting SSTR2-positive neuroendocrine tumours.
引用
- Xia Y, Zeng C, Zhao Y, et al. Comparative evaluation of 68Ga-labelled TATEs: the impact of chelators on imaging. EJNMMI Res. 2020. PMID: 32297029. doi:10.1186/s13550-020-00620-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。